LobbyingWeil, Gotshal & Manges lobbying by quarter
Weil, Gotshal & Manges's latest lobbying report covers Q1 2024, at under $5,000. Its first report covers Q3 2023; the issues it reports most are Health Issues.
Weil, Gotshal & Manges
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q3 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2023 | $30K | 1 |
| Q4 2023 | $90K | 1 |
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$120K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- SENATE3 reports
- HOUSE OF REPRESENTATIVES2 reports
Firms it paid
| Firm | ||
|---|---|---|
| FGS Global | $120K | 3 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/04/22for Q1 2024 | FGS Global | Under $5,000 |
| 24/01/18for Q4 2023 | FGS Global | $90K |
| 23/10/19for Q3 2023 | FGS Global | $30K |
| 23/09/28for Q3 2023 | FGS Global | Under $5,000 |